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Abstract
Pneumococcal-associated hemolytic uremic syndrome ( pHUS) is a rare but severe complication of invasive Streptococcus
pneumoniae infection. We report the case of a 12-year-old female with steroid-resistant nephrotic syndrome treated with
adrenocorticotrophic hormone (H.P. Acthar® Gel), who developed pneumococcal pneumonia and subsequent pHUS. While
nephrotic syndrome is a well-known risk factor for invasive pneumococcal disease, this is the ﬁrst reported case of pHUS in an
adolescent patient with nephrotic syndrome, and reveals novel challenges in the diagnosis, treatment and potential prevention
of this complication.
Key words: Acthar, hemolytic, nephrotic, streptococcus, uremic

Background
Hemolytic uremic syndrome (HUS) is characterized by the triad
of microangiopathic hemolytic anemia, thrombocytopenia
and acute renal failure. HUS in children is most commonly
caused by Shiga-like toxin-producing Escherichia coli (STEC),
with pneumococcal-associated HUS ( pHUS) accounting for
5% of acquired cases. Most cases occur in neonates and children
<2 years of age. The clinical course and overall outcomes of pHUS
are severe. Up to 85% of patients require dialysis with a mortality
rate of >10% [1, 2]. The inciting event is endothelial damage
activating a microangiopathic cascade of thrombotic vascular
injury. Streptococcus pneumoniae cleaves N-acetylneuraminic acid
(sialic acid) and exposes the Thomsen–Friedenreich antigen
(T-antigen) on glomerular endothelial cell glycoproteins [3].
This process, known as T-activation, then leads to IgM binding
from circulating IgM anti-T antibodies, and the clinical syndrome
of HUS (Figure 1) [4].

Treatment of pHUS is with antibiotics with activity against
S. pneumoniae and supportive care. If necessary, transfusion of
washed blood products is preferable to avoid increasing the levels
of preformed anti-T antibodies, which are high in unwashed
products. Anecdotal evidence supports the use of plasma exchange with 5% albumin replacement, and avoiding fresh frozen
plasma (FFP) due to preformed anti-T antibodies in the pooled
product [5–7].

Case report
A 12-year-old female with steroid-resistant nephrotic syndrome
presented to the emergency department with fever, shortness of
breath and cough. On exam she was tachycardic and tachypneic,
requiring 3 L of supplemental oxygen. She was given 1 L of normal
saline bolus intravenously. A chest X-ray identiﬁed bilateral pulmonary edema. She met criteria for sepsis [8]. She was started
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Fig. 1. A mechanism of endothelial cell injury in Streptococcal Pneumoniae associated hemolytic uremic syndrome.

Table 1. Pertinent laboratory data
Laboratory test

Admission (Day 1)

After PLEX (Day 8)

Day 25

Reference

Hemoglobin (g/dL)
Hematocrit (%)
Platelet count (×109/L)
Lactate dehydrogenase (U/L)
Bilirubin (mg/dL)
Blood urea nitrogen (mg/dL)
Creatinine (mg/dL)
Fibrinogen (mg/dL)
PT/aPTT (in seconds)
DCT
ADAMST13
Smear (Schistocytes)

7.4
22.6
100
294
0.1
30
1.4
737
19.4/48.6
NA
72%
Positive

8.6
26.4
81
NA
0.9
10
1.9
426
21.1/43.9
Negative

10.1
29.5
225
NA
NA
50
8
NA
NA
Positive

12.1–15.1
36.1–44.3
140–440
100–250
0–0.4
9.0–18.0
0.2–0.8
177–401
12–16.1/23–40.6
Negative
≥70%
Negative

ADAMST13, a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13; DCT, direct Coombs test; NA, not available/not obtained; PLEX, plasma
exchange; PT/aPTT, prothrombin time/activated partial thromboplastin time.

on vancomycin and cefotaxime, and admitted to our pediatric intensive care unit for further management.
Past medical history was remarkable for the diagnosis of
nephrotic syndrome at the age of 5 years. Although initially responsive to steroids she suffered several relapses when the steroid dose was tapered. At the age of 6 years a renal biopsy showed
ﬁndings consistent with minimal change disease. Genetic testing
for inherited nephrotic syndromes identiﬁed a heterozygous,
non-coding mutation in the transient receptor potential cation channel subfamily C member 6 (TRPC6) gene of unknown clinical
signiﬁcance. She was given an 8-week course of cyclophosphamide, which induced a 1.5-year remission. After relapse and a
failed attempt to induce full remission with oral steroids she
was started on tacrolimus. Over the next 3 years she had a partial
clinical response, with improved edema but persistent proteinuria. Out of concern for missed focal segmental glomerular sclerosis (FSGS) and long-term calcineurin inhibitor nephrotoxicity, a
repeat biopsy was performed. Biopsy showed interstitial nephritis without evidence of FSGS. Due to drug-resistant nephrotic
syndrome and biopsy ﬁndings suggesting possible drug injury
she was started on a trial of adrenocorticotrophic hormone

(H.P. Acthar® Gel; Mallinckrodt Pharmaceuticals, St Louis, MO,
USA) twice weekly in addition to tacrolimus. She received
Acthar® for 2 months prior to presentation.

In the intensive care unit
An initial blood culture grew out S. pneumoniae at 8 h, and a nasopharyngeal swab PCR was positive for parainﬂuenza type 2. Overnight the patient developed oliguria, the creatinine increased
from 1.4 to 2.4 mg/dL, and the hemoglobin decreased from 11.4 to
7.4 g/dL (Table 1). Acthar® and tacrolimus were discontinued. She
was transfused one unit of unwashed packed red blood cells
(pRBCs) and started on continuous veno-venous hemodiaﬁltration
due to worsening kidney function and pulmonary edema.
On hospital day 4 she developed respiratory failure requiring
intubation. A computed tomography scan of the chest demonstrated
bilateral patchy consolidation consistent with bronchopneumonia, and bilateral pleural effusions. High-dose hydrocortisone
was administered due to concern for adrenal suppression from
chronic steroid/Acthar® administration. The platelet count continued to decrease and her clinical condition worsened, requiring
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Table 2. Pneumococcal immunization recommendations in nephrotic syndrome
ACIP recommendations for PCV13 and PPSV23 administration in children aged 6–18 years old with immunocompromising conditions (including
nephrotic syndrome)

Patients who have NOT previously
received PPSV23
Patients who have previously received
PPSV23

PCV13

PPSV23

PPSV23

1 dose

1st dose ≥8 weeks after
PCV13 dose
N/A—already received 1st
dose

2nd dose ≥5 years after 1st
PPSV23 dose
≥5 years after 1st PPSV23 dose

1 dose ≥8 weeks after last
PPSV23 dose

ACIP, Advisory Committee on Immunization Practices; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.

intravenous vasoactive support. A 5-day course of plasma exchange (PLEX) was started. Initially the presumed mechanism
for her worsening clinical course was the development of
thrombocytopenia-associated multiple organ failure; therefore,
FFP was used as the replacement ﬂuid during the exchange [9].
The possibility of pHUS was raised shortly after initiation of
PLEX and the lack of clinical response to replacement with FFP.
A direct Coombs test was checked and came back negative; however, a false negative could be explained by the removal of plasma antibodies from PLEX [10]. Indeed, a follow-up direct Coombs
test drawn after completion of PLEX was positive.
The platelet count reached a nadir of 36 on Day 13, after
which it slowly improved without the need for transfusion.
With supportive care, antibiotics and temporary kidney replacement therapy (KRT), the patient slowly recovered. She was eventually discharged home on hospital day 39, her creatinine having
returned to the baseline level of 0.6 mg/dL. She is currently on
angiotensin-converting enzyme inhibitor therapy with persistent nephrotic syndrome.

Discussion
Diagnosis of pHUS is based on the association of the clinical triad
of HUS with conﬁrmed or suspected S. pneumoniae infection [11].
Evidence of T-antigen exposure (direct Coombs test, polyagglutination test or peanut lectin agglutination test) can help support
the diagnosis, but is not mandatory [12]. The patient met diagnostic criteria for pHUS, and additionally had a positive direct
Coombs test (Table 1). While disseminated intravascular coagulation (DIC) with multiorgan failure was considered as an alternative diagnosis, it was eventually rejected due to evidence of
autoimmune hemolysis (schistocytes, positive Coombs), and
normal ﬁbrinogen level. Initially the mildly prolonged prothrombin time/activated partial thromboplastin time (PT/aPTT) hinted
toward the possibility of DIC, but coagulation abnormalities are
common in pHUS, and DIC is typically not considered without
signiﬁcant PT/aPTT elongation along with decreased ﬁbrinogen.
One unique aspect of this case was the patient’s age and risk
factors. The median age of pHUS reported in the literature ranges
from 13 to 24 months [1, 13, 14]. Four cases of pHUS in adults have
been reported [15–18]. Two of these patients had undergone
splenectomy, and so underlying immunodeﬁciency is presumably a risk factor for development of pHUS at an older age.
Nephrotic syndrome is a well-known cause of secondary immunodeﬁciency due to multiple factors including edema, urinary
loss of immunoglobulins and complement factors, and secondary effects of cytotoxic therapies [19–21]. Streptococcus pneumoniae
in particular is a major cause of sepsis and peritonitis in

nephrotic syndrome [22], yet this is the ﬁrst reported case of
pHUS in a patient with nephrotic syndrome.
Another potential risk factor in this patient was her exposure
to immunosuppressive agents. Tacrolimus has a well-known
association with HUS, but does not typically cause a positive
Coombs test. Also, in a review of 16 cases of tacrolimus-induced
HUS, the average time from initiating tacrolimus to disease onset
was 7.1 months, while our patient had been treated for over
3 years [23]. In addition to tacrolimus, our patient was started
on Acthar® 2 months prior to presentation. H.P Acthar® Gel is a
repository corticotropin injection that was ﬁrst approved by the
FDA in 1952 for a variety of autoimmune and inﬂammatory
diseases, and is an approved treatment for nephrotic syndrome
[24]. Proposed mechanisms of action include increased endogenous steroidogenesis, immunomodulation via melanocortin
receptor binding and podocyte protection [25]. Adrenocorticotropic hormone (ACTH) therapy is tolerated by most patients, with
adverse effects similar to those of glucocorticoid therapy (weight
gain, bone loss, Cushingoid features). Although we do not suspect a pathogenic role of ACTH in the development of HUS, and
our patient had several risk factors for pneumococcal infection,
it is worth noting this serious complication in the setting of
Acthar® administration.
The clinical course of pHUS is typically more severe than
diarrheal HUS, with more frequent need for dialysis and transfusions, and longer hospital stays [26]. In 2008, Copelovitch and
Kaplan reviewed all previous cases of pHUS reported in the
English literature, and found a 12.3% mortality rate, with 10% progressing to end-stage renal disease, and 16% with chronic kidney
disease and/or hypertension [2]. Management of pHUS is primarily supportive, with prompt administration of antibiotics, transfusions and KRT as needed. FFP and unwashed pRBCs should
be avoided, due to the possibility of increased exposure to antiT antigen IgM antibodies.
Plasma exchange with 5% albumin replacement ﬂuid has
been advocated for the treatment of pHUS due to the theoretical
beneﬁt of removing anti-T IgM antibodies and bacterial neuraminidase. Guidelines rate the indication for plasma exchange
as a category III: optimum role of apheresis therapy is not established and care should be individualized [27]. Further conclusions
cannot be reached without a randomized controlled trial or highpowered case series.
The Advisory Committee on Immunization Practices recommends that children aged 6–18 years with immunocompromising conditions (including nephrotic syndrome) receive both the
13-valent pneumococcal conjugate vaccine (PCV13) and the 23valent pneumococcal polysaccharide vaccine (PPSV23) (Table 2)
[28]. The epidemiology of invasive pneumococcal disease, and
pHUS in particular, has been altered dramatically with the
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introduction of pneumococcal vaccines. Most notably, rates of
invasive pneumococcal disease have plummeted in children
younger than 5 years, and non-vaccine serotypes have risen in
prevalence [29]. The patient received PCV7 vaccination from her
primary pediatrician, but did not receive subsequent PCV13 or
PPSV23. Results of serotyping for this case are still pending,
but the possibility that the infection was caused by a vaccinepreventable serotype underscores the importance of ensuring
vaccine understanding among both community and specialist
pediatricians.
This case highlights the diagnostic challenges that pHUS
presents, and the importance of early recognition. Management
often requires intensive supportive care with dialysis, transfusion with washed blood products and consideration of PLEX
with 5% albumin. This case also highlights the need to consider
pHUS in older patients with immunocompromising conditions
such as nephrotic syndrome that increase the risk of invasive
pneumococcal infection. Finally, proper vaccination practices
are important to help prevent pneumococcal disease and its
associated sequelae.
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